As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price target of ...

Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

NASDAQ:ALMS opened at $4.82 on Tuesday. Alumis has a 1-year low of $4.74 and a 1-year high of $13.53. The company has a 50-day moving average of $7.80 and a 200 day moving average of $10.19.

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...

Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:SLRN) in an all-stock ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger. The resulting company will continue under the Alumis name at the ...

SEATTLE, February 12, 2025--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases ...

Oppenheimer launched its coverage of Alumis (NASDAQ:ALMS) with an Outperform recommendation and a 12–18-month price target of $32 on Thursday, noting that despite the potential in its pipeline ...

Jan. 28, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq ... Prior to Amgen's 2023 acquisition of Horizon Therapeutics, Mr. Danilkowicz spent over a decade at Horizon, where he held several ...